- Press Release -

Omics lab services are set to grow from $75.1Bn in 2026 to $189.5Bn by 2036, a 9.7% CAGR and a $114.4Bn opportunity, Fact.MR finds. Sequencing is the engine. Pharma and biotech firms are outsourcing genomics work to specialist labs, especially in drug discovery. Drug discovery and development leads applications at 32.4% and next-generation sequencing leads technology at 42.1%. The USA, Japan, and Germany grow fastest.

What Research Sponsors Look For

Sponsors want sequencing capacity, clean data, and bioinformatics they do not have to build in-house. Genomics services lead at 38.4% because sequencing sits at the core of most programs. Turnaround and data quality often matter more than headline price. Bundled bioinformatics is increasingly part of the ask, not a separate line item.

Where the Volume Sits

Drug discovery and development leads applications at 32.4%, the largest pool of outsourced work. Next-generation sequencing dominates technology at 42.1%, and genomics services lead service type at 38.4%. Pharma and biotech companies are the top end user at 30.5%, and direct service contracts lead distribution at 30.6%. Sequencing-led genomics for drug programs is the center of demand.

Country-Level Growth Leaders

The USA leads at 12.59% on deep pharma and biotech activity. Japan follows at 11.67%, Germany at 10.69%, the UK at 9.69%, and Canada at 8.69%. North America and advanced economies drive the pace, with drug-discovery outsourcing the common driver.

The Constraints

Sample quality and pre-analytics issues are the first constraint, since bad inputs waste sequencing runs. Data interpretation is a heavy lift that stretches timelines. Genomic data privacy and cross-border rules complicate multi-site work. Strong pre-analytics and bioinformatics support are what separate the labs that deliver.

How Producers Are Responding

Thermo Fisher Scientific, Illumina, and QIAGEN supply platforms and services across the workflow. Eurofins Scientific and Charles River Laboratories offer broad outsourced testing. Agilent Technologies, BGI Genomics, and Bio-Rad Laboratories round out the field. The work is on better pre-analytics, bundled bioinformatics, and compliant data handling.

Signals Worth Tracking

Sequencing capacity and turnaround are the numbers to watch, since they gate throughput. Bioinformatics bundling shapes value. Data-privacy and cross-border rules affect multi-site programs. Sample-quality controls matter for run success, and USA and Asia growth marks the strongest demand.

About the Report

The study segments the omics lab services market by service type, application, end user, distribution channel, technology, and region. It compares country-level growth across North America, Europe, Asia Pacific, Central and South America, and the Middle East and Africa from 2026 to 2036. Research sponsors, service labs, and investors can use it to size demand, benchmark shares, and plan outsourcing and capacity decisions.

About the Company

Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

For more information, refer to our market research report or contact the PR author.